1
Views
2
CrossRef citations to date
0
Altmetric
Original Article

IMxR CA 125TM, an automated microparticle enzyme immunoassay: technical characteristics and clinical usefulness after recalibration

&
Pages 289-294 | Received 07 Nov 1994, Accepted 05 Feb 1995, Published online: 08 Jul 2009
 

Abstract

A recently described automated microparticle enzyme immunoassay (Abbott IMxR CA 125TM) for cancer antigen 125 (CA 125) was recalibrated by the manufacturer to provide better agreement between the results of the IMxR assay and other test methods for CA 125. The recalibrated microparticle enzyme immunoassay (MEIAII) had low imprecision (2.9–11.9%), a low detection limit (less than 0.48 kU 1−1), a low carryover (less than 0.014%), and CA 125 was linearly recovered after dilution. CA 125 was measured during treatment of 138 patients with ovarian cancer and the MEIAII results were closely, but non-linearly, related to antigen values determined by a routinely used manual enzyme immunoassay (EIA) (Abbott CA 125 EIA). EIA levels below 167 kU I−1 resulted in higher values when measured by the MEIAII and CA 125 concentrations above 167 kU 1−1 in the EIA gave lower MEIAII values. CA 125 MEIAII and EIA measurements before a second-look laparotomy of 57 patients with ovarian cancer demonstrated that, using slightly different upper limits of normal values (MEIAII, 27 kU 1−1; EIA, 20 kU 1−1), the clinical information obtained from the MEIAII was equivalent to that obtained from the EIA. In conclusion, switching from the EIA to the MEIAII would indicate that series of samples should be analysed by both methods during a transfer period. The length of the period should depend on the obtained results.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.